Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50%

被引：10
|
作者：
Zarogoulidis, Paul [1 ]
Papadopoulos, Vasilis [2 ]
Maragouli, Elena [2 ]
Papatsibas, George [2 ]
Sardeli, Chrysanthi [3 ]
Man, Yan-Gao [4 ]
Bai, Chong [5 ]
Huang, Haidong [5 ]
机构：
[1] Theageneio Canc Hosp, Pulm Dept, Oncol Unit, Thessaloniki, Greece
[2] Univ Thessaly, Dept Oncol, Larisa, Greece
[3] Aristotle Univ Thessaloniki, Fac Hlth Sci, Sch Med, Dept Pharmacol & Clin Pharmacol, Thessaloniki, Greece
[4] Vet Affair Hlth Syst, Lab Prote & Prot Sci, Baltimore, MD USA
[5] Second Mil Med Univ, Changhai Hosp, Dept Resp & Crit Care Med, Shanghai 200000, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
SMALL BIOPSY; CASE SERIES; STAGE IV; EXPRESSION; SPECIMENS; THERAPY; SAMPLES; UPDATE;
D O I：
10.21037/tlcr.2018.01.04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S28 / S30
页数：3
相关论文
共 50 条
  • [31] Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study
    Gumus, Mahmut
    Chen, Chieh-, I
    Ivanescu, Cristina
    Kilickap, Saadettin
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Harnett, James
    Mastey, Vera
    Naumann, Ulrike
    Reaney, Matthew
    Konidaris, Gerasimos
    Sasane, Medha
    Brady, Keri J. S.
    Li, Siyu
    Gullo, Giuseppe
    Rietschel, Petra
    Sezer, Ahmet
    CANCER, 2023, 129 (01) : 118 - 129
  • [32] First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer ... finally what threshold of PD-L1 expression on tumor cells?
    Hofman, Paul
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 728 - 730
  • [33] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
    Theelen, Willemijn S. M. E.
    Baas, Paul
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [34] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%
    Descourt, Renaud
    Chouaid, Christos
    Perol, Maurice
    Besse, Benjamin
    Greillier, Laurent
    Bylicki, Olivier
    Ricordel, Charles
    Guisier, Florian
    Gervais, Radj
    Schott, Roland
    Auliac, Jean-Bernard
    Robinet, Gilles
    Decroisette, Chantal
    FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016
  • [35] Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ≥50% on first-line pembrolizumab
    Yamaguchi, Ou
    Kaira, Kyoichi
    Shinomiya, Shun
    Mouri, Atsuto
    Hashimoto, Kosuke
    Shiono, Ayako
    Miura, Yu
    Akagami, Tomoe
    Imai, Hisao
    Kobayashi, Kunihiko
    Kagamu, Hiroshi
    THORACIC CANCER, 2021, 12 (03) : 304 - 313
  • [36] Plasma cell free PD-L1 RNA expression correlated with tissue PD-L1 immunohistochemical staining and tumor mutation burden in non-small cell lung cancer.
    Walker, Paul R.
    Bowling, Mark
    Sharma, Nitika
    Namireddy, Praveen
    Parent, Teresa
    Cherry, Cynthia R.
    Yeh, Chen-Hsiung
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%
    Shah, M.
    Marmarelis, M. E.
    Mamtani, R.
    Hubbard, R. A.
    Hennessy, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S369 - S370
  • [38] Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026
    Peters, Solange
    Creelan, Benjamin
    Hellmann, Matthew D.
    Socinski, Mark A.
    Reck, Martin
    Bhagavatheeswaran, Prabhu
    Chang, Han
    Geese, William J.
    Paz-Ares, Luis
    Carbone, David P.
    CANCER RESEARCH, 2017, 77
  • [39] Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
    Cui, H-J.
    Zheng, S-Y.
    ANNALS OF ONCOLOGY, 2019, 30 : 511 - 511
  • [40] Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker
    Aguiar, P.
    Santoro, I.
    Tadokoro, H.
    Filardi, B. A.
    Lopes, G. L.
    Picon, F. S.
    Noia Barreto, C. M.
    Muniz, P. C.
    Borges, A. M.
    Oliveira, P.
    Mountzios, G.
    Riera, R.
    De Mello, R. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S624 - S624
12345